A NEW INDEX FOR ASSESSMENT THE SEVERITY OF COMORBIDITY AND ITS USING IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AT THE BACKGROUND OF CARBOHYDRATE METABOLISM DISORDERS AND CONCOMITANT SUBCLINICAL HYPOTHYROIDISM
Keywords:
non-alcoholic fatty liver disease, index of the severity of comorbid diseases, comorbidity assessment, concomitant subclinical hypothyroidismAbstract
The aim – to develop and describe a new index for comorbidity severity assessment in patients with nonalcoholic fatty liver disease and concomitant subclinical hypothyroidism.
Materials and methods. 226 patients with NAFLD and associated carbohydrate metabolism disorders were examined. Also 60 persons with subclinical hypothyroidism, 30 patients with type 2 diabetes mellitus (without signs of NAFLD) and 30 NAFLD patients (with normal carbohydrate metabolism) were examined. 30 healthy persons were formed the control group. A new index of comorbidity has been used. Calculation of comorbidity severity index (ComSI) includes the possible presence of NAFLD, thyroid disorders, abdominal obesity, dyslipidemia, anemia, chronic complications of T2-DM, aggravated anamnesis.
Results. The using of Comorbidity severity index (ComSI) in the examined patients showed that increasing of patients’ age was associated with increasing of concomitant diseases number and with deteriorating of the patients’ general condition, which is reflected in an increasing of the ComSI value. The increasing of concomitant diseases number associated not only with the higher ComSI, but also with the number of persons with a severe comorbidity according the ComSI value. Instead, persons without comorbidity (groups 6, 7, 8) were marked as the patients with mild or moderate disease according the ComSI.
Conclusions. The ComSI index can be used to evaluate the severity of comorbidity in patients with NAFLD and concomitant T2-DM or pre-diabetes.
References
Свідоцтво на авторське право (заявка № АПС/6712-18 від 27.09.2918) авторів Фейса С.В., Чопей І.В. Методичні рекомендації «Розрахунок індексу важкості перебігу коморбідних захворювань (індекс ВПКЗ)».
American association of clinical endocrinologists and American College of Endocrinology. Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015 // Endocr pract. – 2015. – № 21.
Ballestri S. Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis / S. Ballestri // J Gastroenterol Hepatol. – 2016. – № 31 (5). – p. 936–944. doi: 10.1111/jgh.13264.
Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine / D. Campbell-Scherer // Evid Based Med. – 2010. – № 15. – p. 165-166.
Fawad Aslam Tools for the assessment of comorbidity burden in rheumatoid arthritis / Fawad Aslam, Nasim Ahmed Khan // Front Med (Lausanne). – 2018. – №5. – р. 39. doi: 10.3389/fmed.2018.00039.
Kaplan M.H. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus / M.H. Kaplan, A.R. Feinstein // Diabetes. – 1973. – № 22 (3). – p. 160–174.
Kassem A. Association and impact of non-alcoholic fatty liver disease on thyroid function / A. Kassem, F. Khalil, M. Ramadan et al. // Int. J Curr Res Med Sci. – 2017. – № 3 (7). – р. 94-107. DOI: http://dx.doi.org/10.22192/ ijcrms.2017.03.07.016.
Nascimbeni F. From NAFLD in clinical practice to answers from guidelines / F. Nascimbeni, R. Pais, S. Bellentani et al. // J Hepatol. – 2013. – № 59. – p. 859-871.
Non-alcoholic fatty liver disease. Clinical recommendations of EASL-EASD-EASO // J Hepatol. – 2016. – № 64. – p. 1388-1402.
Vernon G. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults / G. Vernon, A. Baranova, Z.M. Younossi // Aliment Pharmacol Ther. – 2011. – № 34. – p. 274-285. Doi: 10.1111/j.1365-2036.2011.04724.x.
